Rewind Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

Rewind Therapeutics General Information

Description

Developer of remyelinating therapeutics designed to facilitate the treatment of neurological diseases. The company's therapeutics system blocks the inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells to promote effective remyelination, enabling medical practitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Contact Information

Website
www.rwdtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Gaston Geenslaan 3
  • 3001 Leuven
  • Belgium
+32 02
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Gaston Geenslaan 3
  • 3001 Leuven
  • Belgium
+32 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rewind Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 25-Jan-2023 Completed Generating Revenue
4. Later Stage VC (Series A1) 06-Jan-2022 Completed Generating Revenue
3. Grant 01-Aug-2019 Completed Generating Revenue
2. Early Stage VC (Series A) 03-Jul-2019 $10M $28M Completed Generating Revenue
1. Early Stage VC (Series A) 04-Jan-2018 $18M $18M Completed Generating Revenue
To view Rewind Therapeutics’s complete valuation and funding history, request access »

Rewind Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
Series A 39,953 $90.46 $90.46 1x $90.46 20.42%
To view Rewind Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Rewind Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of remyelinating therapeutics designed to facilitate the treatment of neurological diseases. The company's the
Drug Discovery
Leuven, Belgium
19 As of 2023

Edinburgh, United Kingdom
 

Reinach, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rewind Therapeutics Competitors (29)

One of Rewind Therapeutics’s 29 competitors is Macomics, a Venture Capital-Backed company based in Edinburgh, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Macomics Venture Capital-Backed Edinburgh, United Kingdom
SunRegen Venture Capital-Backed Reinach, Switzerland
Mestag Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Genespire Venture Capital-Backed Milan, Italy
Asceneuron Venture Capital-Backed Eysins, Switzerland
You’re viewing 5 of 29 competitors. Get the full list »

Rewind Therapeutics Patents

Rewind Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023401169-A1 Fused pyrrolyl-sulfonamide compounds Pending 02-Dec-2022
EP-4626860-A1 Fused pyrrolyl-sulfonamide compounds Pending 02-Dec-2022
US-20260184679-A1 Fused pyrrolyl-sulfonamide compounds Pending 02-Dec-2022
WO-2024115733-A1 Fused pyrrolyl-sulfonamide compounds Inactive 02-Dec-2022
AU-2022285899-A1 3-pyrrolylsulfonamide compounds as gpr17 antagonists Pending 04-Jun-2021 A61K31/506
To view Rewind Therapeutics’s complete patent history, request access »

Rewind Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rewind Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
AXA Investment Managers Asset Manager Minority
Sunstone Life Science Ventures Venture Capital Minority
VLAIO Limited Partner
Axxam PE-Backed Company Minority
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Rewind Therapeutics FAQs

  • When was Rewind Therapeutics founded?

    Rewind Therapeutics was founded in 2017.

  • Where is Rewind Therapeutics headquartered?

    Rewind Therapeutics is headquartered in Leuven, Belgium.

  • What is the size of Rewind Therapeutics?

    Rewind Therapeutics has 19 total employees.

  • What industry is Rewind Therapeutics in?

    Rewind Therapeutics’s primary industry is Drug Discovery.

  • Is Rewind Therapeutics a private or public company?

    Rewind Therapeutics is a Private company.

  • What is Rewind Therapeutics’s current revenue?

    The current revenue for Rewind Therapeutics is .

  • How much funding has Rewind Therapeutics raised over time?

    Rewind Therapeutics has raised $31.6M.

  • Who are Rewind Therapeutics’s investors?

    AXA Investment Managers, Sunstone Life Science Ventures, VLAIO, Axxam, and Boehringer Ingelheim Venture Fund are 5 of 9 investors who have invested in Rewind Therapeutics.

  • Who are Rewind Therapeutics’s competitors?

    Macomics, SunRegen, Mestag Therapeutics, Genespire, and Asceneuron are some of the 29 competitors of Rewind Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process